Elder Pharmaceuticals Limited
NSE Symbol ELDERPHARM
Q2 FY 2011 - SEPT 2010 QE RESULTS
Elder Pharmaceuticals ranked as the 28th (ORG-IMS) largest pharmaceutical company commenced operations in 1989.It is rated as the third fastest growing company, by revenue, in the pharmaceutical industry in FY 2007 in India.
Elder Pharmaceuticals principal activities include manufacturing and marketing of prescription pharmaceutical brands, surgical and medical devices. Shelcal, Elder’s No.1 brand, is one of the top brands in the Indian Pharmaceutical industry. Elder Phara is one of the leading players in the pharmaceutical formulation market in India, being a market leader in three therapeutic segments - Women’s Healthcare, Wound Care and Nutraceuticals.
Elder has a number of strategic alliances with a number of international pharmaceutical entities for marketing their products in India and has made good overseas international acquisitions.
Elder manufactures API and formulations across 6 manufacturing plants in India and one in Nepal possessing a capability to manufacture various dosage forms like tablets, capsules, syrups, injectibles, topical creams and ointments.
Over the years, Elder upgraded its capacities in line with international standards to cater to the requirements of a wider patient community. Even as it upgraded its facilities, it also invested in capacity expansion through investments in internationally benchmarked greenfield facilities.
ELDER PHARMA has produced good results for q/3 Sept 2010.
Net Sales for q/e sep 2010 is Rs. 204.05 Cr – up by 6.78% from previous qtr and by 20.46% from last year’s corresponding qtr.
Profit from Operations is Rs.36.25 Cr – up by 4.89% from previous Qtr – and by 28.97% from corresponding qtr.
Net Profit is Rs.16.14 Cr – down by 14.53% from previous qtr (due to decrease in other income and increase in Tax expense) but UP BY39.21% from corresponding qtr.
Basic EPS is Rs.8.5 on a FV of Rs.10 – against Rs.10.01 in previous qtr and Rs.7.23 in corresponding qtr.
RESULTS IN NUMBERS :
| ELDER PHARMA | |||||
| 10-sep | 10-jun | Dif%1 | Sep09 | Dif%2 | |
| Net Sales | 20405.23 | 19108.96 | 6.78 | 16939.3 | 20.46 |
| Other Oprtg | 19.8 | 16.09 | 23.06 | 9.55 | 107.33 |
| SIT & WIP | 834.14 | -633.66 | -231.6 | -1800.43 | -146.33 |
| Raw Materials | 2352.32 | 3292.63 | -28.56 | 2623.42 | -10.33 |
| Traded Goods | 6584.57 | 6262.18 | 5.15 | 7220.98 | -8.81 |
| Employees Cost | 2664.84 | 2547.03 | 4.63 | 2474.86 | 7.68 |
| Depreciation | 738.49 | 494.96 | 49.2 | 352.5 | 109.5 |
| Other Expend | 3625.44 | 3705.81 | -2.17 | 3266.69 | 10.98 |
| Total Expend | 16799.8 | 15668.95 | 7.22 | 14138.02 | 18.83 |
| Profit from Oper | 3625.23 | 3456.1 | 4.89 | 2810.83 | 28.97 |
| Other Income | 118.76 | 205.91 | -42.32 | 180.17 | -34.08 |
| Interest | 1417.6 | 1373.18 | 3.23 | 1377.42 | 2.92 |
| Exceptio.Items | 137.87 | 100.96 | 36.56 | - | |
| P B T | 2188.52 | 2187.87 | 0.03 | 1613.58 | 35.63 |
| Tax expense | 575 | 300 | 91.67 | 250 | 130 |
| P A T | 1613.52 | 1887.87 | -14.53 | 1363.58 | 18.33 |
| Extrao.Items | - | - | 204.56 | ||
| Net Profit | 1613.52 | 1887.87 | -14.53 | 1159.02 | 39.21 |
| Face Value | 10 | 10 | 0 | 10 | 0 |
| Paid Up Equity | 2053.69 | 1885.74 | 8.91 | 1885.74 | 8.91 |
| Basic EPS | 8.5 | 10.01 | -15.08 | 7.23 | 17.57 |
| Public holding (%) | 62.79 | 59.48 | 5.56 | 60.11 | 4.46 |
NEWS DT : October 02, 2010
"The company has 61 per cent stake in Elder Biomedia AD, through the company's wholly owned subsidiary in Dubai... (it) has further been increased to 92.2 per cent," Elder Pharma said in a filing to the Bombay Stock Exchange (BSE).
Elder Pharma had earlier made an offer to acquire UK-based NeutraHealth Plc for nearly 9.80 million pounds (about Rs 70.60 crore) to be executed through the company's wholly-owned subsidiary in Dubai.
Europe remains an attractive market to launch pharmaceutical products, because centralised regulatory ruling allows for immediate access to all member states.
* * * E N D * * *
No comments:
Post a Comment